Can Infliximab Serve As a New Therapy for Neuropsychiatric Symptoms?

Can Infliximab Serve As a New Therapy for Neuropsychiatric Symptoms? Publisher Pubmed

Rahmatidehkordi F^{1, 2, 3} ; Birang N⁴ ; Jalalian MN⁵ ; Tamtaji Z⁶ ; Dadgostar E^{7, 8} ; Aschner M⁹ ; Shafiee Ardestani M¹⁰ ; Jafarpour H¹¹ ; Mirzaei H¹² ; Nabavizadeh F^{2, 3} ; Tamtaji OR^{2, 3}

Show Affiliations

1. Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran
2. Electrophysiology Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
3. Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
4. Department of Physical Medicine and Rehabilitation, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
5. Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
6. Student Research Committee, Kashan University of Medical Sciences, Kashan, Iran
7. Behavioral Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
8. Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran
9. Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, 10461, NY, United States
10. Department of Radio Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
11. Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
12. Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran

Source: Naunyn-Schmiedeberg's Archives of Pharmacology Published:2025

Abstract

Neuropsychiatric disorders present a global challenge to public health. Mechanisms associated with neuropsychiatric disorders etiology include apoptosis, oxidative stress, and neuroinflammation. Tumor necrosis factor alpha, an inflammatory cytokine, mediates pathophysiology of neuropsychiatric disorders. Therefore, its inhibition by infliximab might afford a valuable target for intervention. Infliximab is commonly used to treat inflammatory diseases, including ulcerative colitis, Crohn’s disease, and rheumatoid arthritis. Recently, it has been shown that infliximab improves cognitive dysfunction, depression, anxiety, and life quality. Here, we review contemporary knowledge supporting the need to further characterize infliximab as a potential treatment for neuropsychiatric disorders. © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024.

2. Promising Effect of Infliximab on the Extent of Involvement in Ulcerative Colitis, Journal of Research in Medical Sciences (2011)

Experts (# of related papers)

Peyman Adibi (1)

Style	Citing Format
MLA	Rahmatidehkordi F, et al.. "Can Infliximab Serve As a New Therapy for Neuropsychiatric Symptoms?." Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 398, no. 2, 2025, pp. 1081-1097.
APA	Rahmatidehkordi F, Birang N, Jalalian MN, Tamtaji Z, Dadgostar E, Aschner M, Shafiee Ardestani M, Jafarpour H, Mirzaei H, Nabavizadeh F, Tamtaji OR (2025). Can Infliximab Serve As a New Therapy for Neuropsychiatric Symptoms?. Naunyn-Schmiedeberg's Archives of Pharmacology, 398(2), 1081-1097.
Chicago	Rahmatidehkordi F, Birang N, Jalalian MN, Tamtaji Z, Dadgostar E, Aschner M, Shafiee Ardestani M, et al.. "Can Infliximab Serve As a New Therapy for Neuropsychiatric Symptoms?." Naunyn-Schmiedeberg's Archives of Pharmacology 398, no. 2 (2025): 1081-1097.
Harvard	Rahmatidehkordi F et al. (2025) 'Can Infliximab Serve As a New Therapy for Neuropsychiatric Symptoms?', Naunyn-Schmiedeberg's Archives of Pharmacology, 398(2), pp. 1081-1097.
Vancouver	Rahmatidehkordi F, Birang N, Jalalian MN, Tamtaji Z, Dadgostar E, Aschner M, et al.. Can Infliximab Serve As a New Therapy for Neuropsychiatric Symptoms?. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025;398(2):1081-1097.
BibTex	@article{ author = {Rahmatidehkordi F and Birang N and Jalalian MN and Tamtaji Z and Dadgostar E and Aschner M and Shafiee Ardestani M and Jafarpour H and Mirzaei H and Nabavizadeh F and Tamtaji OR}, title = {Can Infliximab Serve As a New Therapy for Neuropsychiatric Symptoms?}, journal = {Naunyn-Schmiedeberg's Archives of Pharmacology}, volume = {398}, number = {2}, pages = {1081-1097}, year = {2025} }
RIS	TY - JOUR AU - Rahmatidehkordi F AU - Birang N AU - Jalalian MN AU - Tamtaji Z AU - Dadgostar E AU - Aschner M AU - Shafiee Ardestani M AU - Jafarpour H AU - Mirzaei H AU - Nabavizadeh F AU - Tamtaji OR TI - Can Infliximab Serve As a New Therapy for Neuropsychiatric Symptoms? JO - Naunyn-Schmiedeberg's Archives of Pharmacology VL - 398 IS - 2 SP - 1081 EP - 1097 PY - 2025 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract